| 1 |
35181316 | Sensitive UHPLC-MS/MS quantification method for 4β- and 4α-hydroxycholesterol in plasma for accurate CYP3A phenotyping. | 2022 Mar |
2 |
| 2 |
33201347 | Serum 4β-hydroxycholesterol increases during fluconazole treatment. | 2021 May |
1 |
| 3 |
33822485 | PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction. | 2021 Jun |
1 |
| 4 |
34572915 | CYP3A Activity in End-of-Life Cancer Patients Measured by 4β-Hydroxycholesterol/cholesterol Ratio, in Men and Women. | 2021 Sep 18 |
2 |
| 5 |
34580385 | Effect of CYP3A4 metabolism on sex differences in the pharmacokinetics and pharmacodynamics of zolpidem. | 2021 Sep 27 |
1 |
| 6 |
32537715 | Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach. | 2020 Jul |
2 |
| 7 |
32656158 | Development and validation of a method for the simultaneous quantification of endogenous steroids metabolized by CYP3A. | 2020 Jun |
1 |
| 8 |
30058048 | Drug-metabolizing enzymes CYP3A as a link between tacrolimus and vitamin D in renal transplant recipients: is it relevant in clinical practice? | 2019 Jul |
1 |
| 9 |
30748026 | 4β-Hydroxycholesterol as an Endogenous Biomarker for CYP3A Activity: Literature Review and Critical Evaluation. | 2019 May |
4 |
| 10 |
30826567 | Factors involved in phenoconversion of CYP3A using 4β-hydroxycholesterol in stable kidney transplant recipients. | 2019 Apr |
2 |
| 11 |
30858735 | Modeling and simulation of the endogenous CYP3A induction marker 4β-hydroxycholesterol during enasidenib treatment. | 2019 |
1 |
| 12 |
31002385 | Use of 4β-Hydroxycholesterol Plasma Concentrations as an Endogenous Biomarker of CYP3A Activity: Clinical Validation in Individuals With Type 2 Diabetes. | 2019 Oct |
1 |
| 13 |
29117990 | Simultaneous Physiologically Based Pharmacokinetic (PBPK) Modeling of Parent and Active Metabolites to Investigate Complex CYP3A4 Drug-Drug Interaction Potential: A Case Example of Midostaurin. | 2018 Feb |
2 |
| 14 |
29279486 | Differences in the Serum 4β-hydroxycholesterol Levels of Patients with Chronic Hepatitis C Virus (HCV) Infection: A Possible Impact on the Efficacy and Safety of Interferon (IFN)-free Treatment. | 2018 May 1 |
3 |
| 15 |
29464732 | Was 4β-hydroxycholesterol ever going to be a useful marker of CYP3A4 activity? | 2018 Jul |
1 |
| 16 |
29649093 | Comparison of CYP3A4-Inducing Capacity of Enzyme-Inducing Antiepileptic Drugs Using 4β-Hydroxycholesterol as Biomarker. | 2018 Aug |
2 |
| 17 |
29691891 | Kuypers and Vanhove reply to 'Was 4β-hydroxycholesterol ever going to be a useful marker of CYP3A4 activity?' by Neuhoff and Tucker. | 2018 Jul |
1 |
| 18 |
29749106 | Gjestad et al. reply to 'Was 4β-hydroxycholesterol ever going to be a useful marker of CYP3A4 activity?' by Neuhoff and Tucker. | 2018 Jul |
1 |
| 19 |
29759884 | Assessment of induced CYP3A activity in pregnant women using 4β-hydroxycholesterol: Cholesterol ratio as an appropriate metabolic marker. | 2018 Jun |
3 |
| 20 |
29858698 | Evaluation of 4β-Hydroxycholesterol and 25-Hydroxycholesterol as Endogenous Biomarkers of CYP3A4: Study with CYP3A-Humanized Mice. | 2018 Apr 9 |
1 |
| 21 |
29991576 | Associations between Cytokine Levels and CYP3A4 Phenotype in Patients with Rheumatoid Arthritis. | 2018 Oct |
1 |
| 22 |
30340067 | Quantitative analysis of 4β- and 4α‑hydroxycholesterol in human plasma and serum by UHPLC/ESI-HR-MS. | 2018 Nov 15 |
3 |
| 23 |
27138546 | An Exposure-Response Modeling Approach to Examine the Relationship Between Potency of CYP3A Inducer and Plasma 4β-Hydroxycholesterol in Healthy Subjects. | 2017 Jan |
1 |
| 24 |
27718639 | Perspective: 4β-hydroxycholesterol as an emerging endogenous biomarker of hepatic CYP3A. | 2017 Feb |
6 |
| 25 |
27777246 | Managing the Risk of CYP3A Induction in Drug Development: A Strategic Approach. | 2017 Jan |
1 |
| 26 |
27975131 | Impact of genetic and nongenetic factors on interindividual variability in 4β-hydroxycholesterol concentration. | 2017 Mar |
1 |
| 27 |
27991741 | 4β-Hydroxycholesterol Level in Patients With Rheumatoid Arthritis Before vs. After Initiation of bDMARDs and Correlation With Inflammatory State. | 2017 Jan |
1 |
| 28 |
28146606 | The CYP3A biomarker 4β-hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation. | 2017 Jul |
1 |
| 29 |
28585378 | 4β-Hydroxycholesterol level significantly correlates with steady-state serum concentration of the CYP3A4 substrate quetiapine in psychiatric patients. | 2017 Nov |
2 |
| 30 |
28603840 | Pretransplant 4β-hydroxycholesterol does not predict tacrolimus exposure or dose requirements during the first days after kidney transplantation. | 2017 Nov |
1 |
| 31 |
28928137 | Recovery of CYP3A Phenotype after Kidney Transplantation. | 2017 Dec |
1 |
| 32 |
26399557 | Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P450 3A Activity and Single-Time-Point Oral Midazolam Microdose Phenotype in Healthy Subjects. | 2016 Apr |
3 |
| 33 |
26574235 | 4β-hydroxycholesterol correlates with dose but not steady-state concentration of carbamazepine: indication of intestinal CYP3A in biomarker formation? | 2016 Feb |
3 |
| 34 |
26805594 | Use of 4β-hydroxycholesterol in animal and human plasma samples as a biomarker for CYP3A induction. | 2016 Feb |
4 |
| 35 |
27138133 | Compelling Relationship of CYP3A Induction to Levels of the Putative Biomarker 4β-Hydroxycholesterol and Changes in Midazolam Exposure. | 2016 Jul |
1 |
| 36 |
27350147 | Recommendations on the Development of a Bioanalytical Assay for 4β-Hydroxycholesterol, an Emerging Endogenous Biomarker of CYP3A Activity. | 2016 Sep |
5 |
| 37 |
27565568 | Rapid LC-MS/MS method for the determination of 4-hydroxycholesterol/cholesterol ratio in serum as endogenous biomarker for CYP3A activity in human and foals. | 2016 Oct 15 |
3 |
| 38 |
26119961 | 4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes. | 2015 Sep |
2 |
| 39 |
26654672 | CYP3A activity based on plasma 4β-hydroxycholesterol during the early postpartum period has an effect on the plasma disposition of amlodipine. | 2015 Dec |
3 |
| 40 |
26773964 | CYP3A5 polymorphism affects the increase in CYP3A activity after living kidney transplantation in patients with end stage renal disease. | 2015 Dec |
1 |
| 41 |
24595680 | 4β-Hydroxycholesterol as an endogenous biomarker of CYP3A activity in cynomolgus monkeys. | 2014 May |
6 |
| 42 |
24837659 | Validation of 4β-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects. | 2014 Nov |
3 |
| 43 |
24839948 | Comparison of two endogenous biomarkers of CYP3A4 activity in a drug-drug interaction study between midostaurin and rifampicin. | 2014 Aug |
2 |
| 44 |
24861746 | Quantitation of P450 3A4 endogenous biomarker - 4β-hydroxycholesterol - in human plasma using LC/ESI-MS/MS. | 2014 Jun |
2 |
| 45 |
24964282 | Evaluation of 4β-Hydroxycholesterol as a Clinical Biomarker of CYP3A4 Drug Interactions Using a Bayesian Mechanism-Based Pharmacometric Model. | 2014 Jun 25 |
7 |
| 46 |
25096076 | Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment. | 2014 Dec |
1 |
| 47 |
23089673 | Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients. | 2013 Dec |
1 |
| 48 |
23386704 | Serum levels of 25-hydroxyvitamin D and the CYP3A biomarker 4β-hydroxycholesterol in a high-dose vitamin D supplementation study. | 2013 Apr |
3 |
| 49 |
23674608 | Comparison of endogenous 4β-hydroxycholesterol with midazolam as markers for CYP3A4 induction by rifampicin. | 2013 Aug |
1 |
| 50 |
23833241 | Significant increase in plasma 4β-hydroxycholesterol concentration in patients after kidney transplantation. | 2013 Sep |
1 |